On Monday, October 27, 2025, Organon announced that CEO Kevin Ali would step down and that Joseph Morrissey, the company’s Executive Vice President and Head of Manufacturing & Supply, would assume the role of interim chief executive officer. The change follows an internal investigation by the audit committee into wholesaler sales practices related to the Nexplanon contraceptive implant. The board also appointed Carrie S. Cox as interim executive chair to support Morrissey.
The audit committee’s review found that certain U.S. wholesalers were asked to purchase more Nexplanon than needed during the fourth quarter of 2022, the third and fourth quarters of 2024, and the first three quarters of 2025. These sales, which represented less than 1% of Organon’s consolidated revenue for the respective years, were deemed improper and led to inaccurate or incomplete prior statements. The investigation concluded that no financial restatement was required, but the company is taking remedial actions to strengthen internal controls.
In connection with the findings, Organon terminated the employment of its Head of U.S. Commercial & Government Affairs and confirmed that the chief financial officer was not aware of the improper practices. The board has also initiated a search for a permanent CEO, engaging a search firm to identify both internal and external candidates. The leadership transition is expected to maintain operational continuity while the company addresses the regulatory and reputational implications of the investigation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.